Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Swine Vaccines Market

Swine Vaccines Market Size

Report ID: GMI10445
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Swine Vaccines Market Size

Swine Vaccines Market size was valued at USD 1.6 billion in 2023 and is expected to exhibit growth at a CAGR of 5.3% from 2024 to 2032. The increasing prevalence of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and African Swine Fever (ASF) compels farmers to adopt vaccination programs to prevent devastating outbreaks. This surge in disease prevalence significantly drives the growth of the market.

To get key market trends

Download Free Sample

Additionally, technological advancements in vaccine development, such as recombinant and DNA vaccines, enhance efficacy and safety, making them more appealing to swine producers and further fueling market growth. Furthermore, government initiatives and support for vaccination programs, coupled with improved veterinary services and distribution networks, facilitate market expansion. Additionally, heightened awareness about animal healthcare and welfare among farmers leads to greater vaccine adoption, reinforcing the market's upward trajectory.

Swine Vaccines Market Report Attributes
Report Attribute	Details
Base Year:	2023
Swine Vaccines Market Size in 2023:	USD 1.6 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	5.3%
2032 Value Projection:	USD 2.5 Billion
Historical Data for:	2021 - 2023
No. of Pages:	126
Tables, Charts & Figures:	226
Segments covered:	Product, Disease Type, End-user, and Region
Growth Drivers:	Rising incidence of swine diseases Growing consumption of pork Increasing government initiatives and support
Pitfalls & Challenges:	High cost of vaccine development

Learn more about the key segments shaping this market

Download Free Sample

Swine vaccines are immunological products designed to protect pigs from infectious diseases, enhancing their health, productivity, and welfare. These animal vaccines stimulate the pig's immune system to develop immunity against specific pathogens, preventing outbreaks and reducing economic losses in the swine industry. Commonly targeted diseases include Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and swine influenza. Swine vaccines are essential tools in veterinary medicine, ensuring the sustainability and biosecurity of pig farming operations.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global swine vaccines industry was valued at USD 1.6 billion in 2023 and is anticipated to record a CAGR of 5.3% through 2032, backed by the increasing prevalence of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and African Swine Fever (ASF).

The inactivated vaccines segment accounted for USD 568.4 million in 2023, owing to their proven track record in preventing swine diseases, along with fewer side effects and adverse reactions, leading to widespread acceptance and trust among farmers and veterinarians.

In 2023, North America market was valued at USD 633.6 million and is expected to record a CAGR of 5.1% from 2024 to 2032, backed by the advanced veterinary infrastructure, supporting efficient vaccine distribution, administration, and monitoring, ensuring high vaccination coverage and effectiveness.

Ceva Sante Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck & Co., Inc., Phibro Animal Health Corporation, Vaxxinova, Virbac, and Zoetis Inc. among others.